Karin Hansson

Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden.

Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.

Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden.

Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013.

Scandibio Therapeutics AB is a Swedish company that specializes in omics data integration, including transcriptomics, proteomics, metabolomics, and metagenomics, using biological networks. Scandibio Therapeutics is based in Stockholm, SE, and was founded by Karin Marianne Hansson, who has been the CEO since incorporation. The private company also study host-microbiome interactions to understand whole body metabolism in health and diseases. The company employs the latest technology and science, such as genome-scale metabolic models, protein-protein interaction networks, transcriptional regulatory networks, signaling networks, metabolic co-factors, host metabolism, microbiome analysis, and clinical studies.

Amylonix AB develops pharmaceuticals focused on the neurodegenerative area. Amylonix AB is based in Johanneshov, Sweden. It was founded in 2018 by Karin Marianne Hansson, who has been the CEO since 2018.